Am J Perinatol
DOI: 10.1055/a-2748-7043
Original Article

Association of Fetal Heart Rate Tracing with Adverse Neonatal Outcomes at 320/7 to 366/7 Weeks

Authors

  • Christina N. Cortes

    1   Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at UTHealth Houston, Houston, Texas, United States
  • Kristen A. Cagino

    1   Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at UTHealth Houston, Houston, Texas, United States
  • Aaron W. Roberts

    1   Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at UTHealth Houston, Houston, Texas, United States
  • Rachel L. Wiley

    2   Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Diego, San Diego, California, United States
  • Shareen Patel

    1   Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at UTHealth Houston, Houston, Texas, United States
  • Fabrizio Zullo

    3   Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Rome, Italy
  • Hector Mendez-Figueroa

    1   Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at UTHealth Houston, Houston, Texas, United States
  • Suneet P. Chauhan

    4   Delaware Center for Maternal-Fetal Medicine of ChristianaCare, Newark, Delaware, United States

Abstract

Objective

The objective of this study is to determine if patterns of fetal heart rate tracings (FHRT) were associated with an increased rate of composite adverse neonatal outcomes (CANO) among preterm deliveries at 320/7 to 366/7 weeks.

Study Design

This was a retrospective review of intrapartum FHRT between 20 and 120 minutes before birth, among nonanomalous singletons delivered at 320/7 to 366/7 weeks. The study was conducted at a Level IV maternal center during a consecutive 15-month period. Obstetricians reviewing FHRT were blinded to the maternal characteristics, intrapartum course, and neonatal outcomes. FHRT patterns were categorized based on time spent in the final 2 hours before delivery (<50 vs. ≥50%). The primary outcome was the CANO, which included any of the following: 5-minute Apgar < 7, mechanical ventilation > 6 hours, umbilical artery pH < 7.00, bronchopulmonary dysplasia, interventricular hemorrhage, necrotizing enterocolitis, neonatal seizures, neonatal confirmed sepsis, hypoxic ischemic encephalopathy, birth injury, meconium aspiration syndrome, or neonatal death.

Results

Of 5,160 patients, 672 (13%) met the inclusion criteria. CANO occurred in 57 (8.5%) newborns. Overall, FHRT patterns that differed significantly between those without versus with CANO included minimal variability (8.8 vs. 19.3%, p = 0.01, PLR = 2.2 [positive likelihood ratio], PPTP 17% [positive posttest probability]), moderate variability (76.4 vs. 52.6%, p < 0.001, NLR = 2.01 [negative likelihood ratio], NPTP 15.7% [negative posttest probability]), accelerations (58.4 vs. 40.4%, p = 0.009, NLR = 1.43, NPTP = 11.7%), and severe variable decelerations (3.5% p = 0.003, PLR = 10.79, PPTP = 50.1%). Category III FHRT pattern was also associated with an increased posttest probably of CANO (0.3 vs. 1.8%, p = 0.12, PLR = 5.39, PPTP = 27%).

Conclusion

While moderate variability and accelerations were associated with significantly lower likelihood of CANO among newborns delivered at 320/7 to 366/7 weeks, minimal variability and severe variable decelerations were significantly more common in preterm newborns with CANO.

Key Points

  • At 32 to 36 weeks, CANO occur in approximately 8% of neonates.

  • Severe variable decelerations and minimal variability increase risk of CANO.

  • The PPTP of CANO is 33%, if Category III FHRT is noted before birth.

  • The PPTP is 13%, if there is persistent Category II FHRT in the last 120 minutes.



Publication History

Received: 29 September 2025

Accepted: 16 November 2025

Accepted Manuscript online:
18 November 2025

Article published online:
29 November 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA